Stockscreener 앱 받기
27.67
2.07%
0.56
시간 외 거래:
26.72
-0.95
-3.43%
Beam Therapeutics Inc 주식(BEAM)의 최신 뉴스
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Beam Therapeutics eyes sickle cell BLA as Alpha-1 gene-editing program advances - MSN
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances - Yahoo Finance
BEAM: Lead gene editing programs advance toward approval with strong efficacy, safety, and payer value - TradingView
Beam Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Two Programs That Could Make or Break Beam Therapeutics Inc (BEAM) Stock - Insider Monkey
In Vivo Gene Editing Market is expected to Hit US$ 37.75 Billion - openPR.com
10 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Beam Therapeutics (BEAM) Is Down 12.0% After Narrowing Losses And Positive BEAM-302 Data Update – Has The Bull Case Changed? - Sahm
Beam Therapeutics Data Puts BEAM 302 And AAT Disease In Focus - Yahoo Finance
Beam Therapeutics (BEAM) Advances Phase 1/2 Trial for AAT Deficiency - GuruFocus
Verve Therapeutics : VERV - 24/7 Wall St.
Beam Therapeutics presents AATD gene therapy trial data at ATS By Investing.com - Investing.com Australia
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference - The Manila Times
One-time gene-editing AATD therapy BEAM-302 seeks accelerated FDA path - Stock Titan
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? - Yahoo Finance
BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data - Stocktwits
Beam Therapeutics Inc (BEAM) Stock Price, Quote, News & History - Benzinga
HC Wainwright Expects Lower Earnings for Beam Therapeutics - MarketBeat
BEAM News Today | Why did Beam Therapeutics stock go up today? - MarketBeat
BEAM's Q1 loss wider than expected, revenues beat estimates - MSN
Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 8%Should You Sell? - MarketBeat
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Beam Therapeutics Stock Stumbles After Post-Rally Shakeout - TipRanks
BEAM Maintained by Bernstein -- Price Target Lowered to $39.00 - GuruFocus
AlphaDetect Partners with Beam Therapeutics to Enhance Detection Efforts - Intellectia AI
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 - ChartMill
Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story - Seeking Alpha
Bernstein Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Cuts Target Price to $39 - Moomoo
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference - The Manila Times
Free genetic tests to spot underdiagnosed Alpha-1 lung and liver risk - Stock Titan
Beam Therapeutics to present sickle cell therapy data at EHA - Investing.com India
Beam Therapeutics to present sickle cell therapy data at EHA By Investing.com - Investing.com South Africa
Beam Therapeutics to Present Positive Biomarker Data from BEACON Trial of Ristoglogene Autogetemcel for Sickle Cell Disease at EHA2026 - Quiver Quantitative
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026 - The Manila Times
Beam Therapeutics to Present Updated Biomarker Data from - GlobeNewswire
(BEAM) Volatility Zones as Tactical Triggers - Stock Traders Daily
Analysts Are Upgrading Beam Therapeutics Inc. (NASDAQ:BEAM) After Its Latest Results - Moomoo
Earnings Update: Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance
Vanguard Group Inc. Sells 57,310 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
Wedbush Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Evercore Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Raises Target Price to $45 - Moomoo
BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Beam Therapeutics (BEAM) - The Globe and Mail
Beam Therapeutics edges higher after new sickle cell therapy results - MSN
MSN Money - MSN
4.72%
0.63%
자본화:
|
볼륨(24시간):